Curis, Inc. (NASDAQ:CRIS – Get Free Report) was the target of a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 168,213 shares, a decline of 48.1% from the August 15th total of 324,276 shares. Currently, 8.5% of the company’s shares are sold short. Based on an average daily volume of 177,225 shares, the days-to-cover ratio is currently 0.9 days.
Hedge Funds Weigh In On Curis
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC acquired a new position in shares of Curis in the second quarter worth about $1,033,171,000. Stonepine Capital Management LLC acquired a new stake in Curis during the 2nd quarter valued at approximately $1,729,292,000. Cable Car Capital LP purchased a new stake in Curis during the 2nd quarter worth approximately $696,000. Flputnam Investment Management Co. purchased a new stake in Curis during the 2nd quarter worth approximately $128,000. Finally, BlackRock Inc. acquired a new position in shares of Curis in the 2nd quarter valued at approximately $28,000. 29.97% of the stock is owned by hedge funds and other institutional investors.
Curis Trading Down 0.9%
NASDAQ:CRIS traded down $0.01 during trading hours on Wednesday, hitting $1.12. The stock had a trading volume of 143,589 shares, compared to its average volume of 123,543. The company has a market cap of $2.34 million, a PE ratio of -0.08 and a beta of 3.01. The business has a 50 day simple moving average of $3.05 and a two-hundred day simple moving average of $8.76. Curis has a 1-year low of $1.07 and a 1-year high of $35.64.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on CRIS. Zacks Research raised shares of Curis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 9th. HC Wainwright reissued a “buy” rating on shares of Curis in a research report on Monday, August 17th. Wall Street Zen raised shares of Curis from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $43.00.
Read Our Latest Analysis on Curis
Curis Company Profile
Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.
Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.
See Also
- Five stocks we like better than Curis
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
